ARID1B

Across TCGA pan-cancer cohorts, ARID1B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ARID1B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARID1B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARID1B is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where ARID1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARID1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−0.234	<.001	9	view →
PDAC	Male	All	−0.226	<.001	8	view →
HNSC	Male	II,III,IV	+0.131	.002	7	view →
LSCC	Male	All	+0.107	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ARID1B–CCRCC

Open the CCRCC breakdown →